# US 2014/0154725 A1 · Insect-based ex vivo model for testing blood-brain barrier penetration and method for exposing insect brain to nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154725 A1
- Document ID: US20140154725A1
- Status: Published application
- Kind: A1
- Application number: 13/881,566
- Filed: 2011-09-30
- Published: 2014-06-05
- Earliest claimed: 2010-10-25
- Assignees: Entomopharm
- Inventors: Peter Aadal Nielsen; Gunnar Andersson; Olga Andersson
- Web page: https://patentgrep.com/patent/US20140154725A1

## CPC

- G01N 33/5058: {Neurological cells}
- G01N 33/5085: {of invertebrates}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

There is provided an ex-vivo insect screening model to accurately determine blood-brain barrier penetration of different nanoparticles in order to improve the compound screening procedures/processes in the early drug discovery process. This object offers many advantages relative to prior technologies since insect models are more reliable tools for the decision-making process than the existing in vitro models, and will speed up the drug screening process and reduce the late phase attrition rate. Moreover, it will reduce the number of mammals sacrificed during the drug discovery phase.

## Claims

### Claim 1

A method of conducting blood-brain barrier penetration studies of nanoparticles in an insect, said method comprising the steps:
optionally anesthetizing the insect;
fixing the head of the insect;
dissecting out the dorsal part of the insect head so as to expose the brain, eyes, antennas, and nerve associations;
optionally removing the neural lamella;
treating the brain with the nanoparticles;
washing and homogenising or ultra sound disintegrating the brain; and
determining the concentration of the nanoparticles in the homogenised brain material.

### Claim 2 (depends on 1)

The method of claim 1, wherein the penetration of the nanoparticles through the blood-brain barrier is calculated.

### Claim 3 (depends on 1)

The method of claim 1, wherein hemolymph and/or albumin is added to the nanoparticles.

### Claim 4 (depends on 1)

The method of claim 1, wherein the concentration of the nanoparticle is determined by LC/MS.

### Claim 5 (depends on 1)

The method of claim 1, wherein the brain is treated with the nanoparticles for a period of 1 min to 2 days.

### Claim 6 (depends on 1)

The method of claim 1, wherein the neural lamella of the brain are removed before the brain is homogenised or ultra sound disintegrated.